Table 11. Results of subgroup analysis by reception of chemotherapy.
| Theme | Received chemotherapy? (e.g., Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Docetaxel, Nab-paclitaxel, Gemcitabine, Etoposide) | ||
|---|---|---|---|
| Prevalence (%) | P value | ||
| Yes | No | ||
| Fatigue | 89.7 | 80.0 | 0.14 |
| Social role dissatisfaction | 50.7 | 39.0 | 0.22 |
| Breathing difficulties | 71.4 | 60.0 | 0.20 |
| Impaired body image | 54.7 | 54.2 | 1.0 |
| Impaired sleep and daytime sleepiness | 75.0 | 71.7 | 0.70 |
| Difficulty thinking | 71.1 | 51.7 | 0.032* |
| Limitations with physical function | 80.3 | 63.3 | 0.034* |
| GI issues | 68.0 | 48.3 | 0.023* |
| Social role limitations | 52.0 | 33.3 | 0.037* |
| Emotional issues | 75.3 | 70.0 | 0.56 |
| Pain | 55.8 | 44.1 | 0.23 |
| Inability to do activities | 66.7 | 55.0 | 0.22 |
| Communication difficulties | 32.0 | 21.7 | 0.24 |
| Choking or swallowing issues | 29.0 | 28.3 | 1.0 |
Prevalence (%) and P values of symptomatic themes evaluated in cross-sectional study subgroup analysis by reception of chemotherapy. *, P<0.05, statistical significance by the Benjamini-Hochberg method. GI, gastrointestinal.